Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial

Gary Wittert, Evan Atlantis, Carolyn Allan, Karen Bracken, Ann Conway, Mark Daniel, Val Gebski, Mathis Grossmann, Wendy Hague, David J. Handelsman, Warrick Inder, Alicia Jenkins, Anthony Keech, Robert McLachlan, Kristy Robledo, Bronwyn Stuckey, Bu B. Yeap

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Low circulating testosterone is associated with an increased risk of developing type 2 diabetes (T2DM) in overweight men with impaired glucose tolerance (IGT). Aims: To determine in a multi-centre, double-blinded placebo-controlled randomized trial whether testosterone treatment combined with lifestyle intervention (Weight Watchers) relative to lifestyle intervention alone reduces T2DM incidence and improves glucose tolerance at 2 years. Study population: Overweight or obese men aged 50-74 years with a serum testosterone of ≤14 nmol/L and IGT or newly diagnosed T2DM established by an oral glucose tolerance test (OGTT). Setting, drug and protocol: Six Australian capital city-based tertiary care centres. Participants were randomized 1:1 and injected with testosterone undecanoate (1000 mg/4 mL) or vehicle (4 mL castor oil), at baseline, 6 weeks and 3-monthly thereafter. Primary endpoints: (a) Proportion of participants with 2-hour OGTT ≥11.1 mmol/L at 2 years, and (b) a difference at 2 years ≥0.6 mmol/L in the mean 2-hour OGTT glucose between treatments. Secondary endpoints: Fasting insulin, HbA1c, body composition, maximal handgrip strength; sexual function and lower urinary tract symptoms; serum sex steroids and sex hormone binding globulin; mood and psychosocial function; adherence to lifestyle intervention; and healthcare utilization and costs. Safety: Overseen by an Independent Data Safety Monitoring Committee. Haematocrit, lipids and prostate-specific antigen (PSA) are assessed 6-monthly and information relating to haematological, urological and cardiovascular adverse events from each clinic visit. Sub-studies: (a) Changes in bone density and micro-architecture, (b) motivation and behaviour, (c) telomere length, (d) extended treatment up to 4 years, and (e) hypothalamo-pituitary testicular axis recovery at treatment end.

LanguageEnglish
Pages772-780
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • body composition
  • cardiovascular
  • motivation
  • obesity
  • prevention
  • testosterone
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Wittert, Gary ; Atlantis, Evan ; Allan, Carolyn ; Bracken, Karen ; Conway, Ann ; Daniel, Mark ; Gebski, Val ; Grossmann, Mathis ; Hague, Wendy ; Handelsman, David J. ; Inder, Warrick ; Jenkins, Alicia ; Keech, Anthony ; McLachlan, Robert ; Robledo, Kristy ; Stuckey, Bronwyn ; Yeap, Bu B. / Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM) : Design and implementation of a double-blind randomized controlled trial. In: Diabetes, Obesity and Metabolism. 2019 ; Vol. 21, No. 4. pp. 772-780.
@article{56d0b9179c3b42d88a787c91b0527a4f,
title = "Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial",
abstract = "Background: Low circulating testosterone is associated with an increased risk of developing type 2 diabetes (T2DM) in overweight men with impaired glucose tolerance (IGT). Aims: To determine in a multi-centre, double-blinded placebo-controlled randomized trial whether testosterone treatment combined with lifestyle intervention (Weight Watchers) relative to lifestyle intervention alone reduces T2DM incidence and improves glucose tolerance at 2 years. Study population: Overweight or obese men aged 50-74 years with a serum testosterone of ≤14 nmol/L and IGT or newly diagnosed T2DM established by an oral glucose tolerance test (OGTT). Setting, drug and protocol: Six Australian capital city-based tertiary care centres. Participants were randomized 1:1 and injected with testosterone undecanoate (1000 mg/4 mL) or vehicle (4 mL castor oil), at baseline, 6 weeks and 3-monthly thereafter. Primary endpoints: (a) Proportion of participants with 2-hour OGTT ≥11.1 mmol/L at 2 years, and (b) a difference at 2 years ≥0.6 mmol/L in the mean 2-hour OGTT glucose between treatments. Secondary endpoints: Fasting insulin, HbA1c, body composition, maximal handgrip strength; sexual function and lower urinary tract symptoms; serum sex steroids and sex hormone binding globulin; mood and psychosocial function; adherence to lifestyle intervention; and healthcare utilization and costs. Safety: Overseen by an Independent Data Safety Monitoring Committee. Haematocrit, lipids and prostate-specific antigen (PSA) are assessed 6-monthly and information relating to haematological, urological and cardiovascular adverse events from each clinic visit. Sub-studies: (a) Changes in bone density and micro-architecture, (b) motivation and behaviour, (c) telomere length, (d) extended treatment up to 4 years, and (e) hypothalamo-pituitary testicular axis recovery at treatment end.",
keywords = "body composition, cardiovascular, motivation, obesity, prevention, testosterone, type 2 diabetes mellitus",
author = "Gary Wittert and Evan Atlantis and Carolyn Allan and Karen Bracken and Ann Conway and Mark Daniel and Val Gebski and Mathis Grossmann and Wendy Hague and Handelsman, {David J.} and Warrick Inder and Alicia Jenkins and Anthony Keech and Robert McLachlan and Kristy Robledo and Bronwyn Stuckey and Yeap, {Bu B.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1111/dom.13601",
language = "English",
volume = "21",
pages = "772--780",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "4",

}

Wittert, G, Atlantis, E, Allan, C, Bracken, K, Conway, A, Daniel, M, Gebski, V, Grossmann, M, Hague, W, Handelsman, DJ, Inder, W, Jenkins, A, Keech, A, McLachlan, R, Robledo, K, Stuckey, B & Yeap, BB 2019, 'Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial', Diabetes, Obesity and Metabolism, vol. 21, no. 4, pp. 772-780. https://doi.org/10.1111/dom.13601

Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM) : Design and implementation of a double-blind randomized controlled trial. / Wittert, Gary; Atlantis, Evan; Allan, Carolyn; Bracken, Karen; Conway, Ann; Daniel, Mark; Gebski, Val; Grossmann, Mathis; Hague, Wendy; Handelsman, David J.; Inder, Warrick; Jenkins, Alicia; Keech, Anthony; McLachlan, Robert; Robledo, Kristy; Stuckey, Bronwyn; Yeap, Bu B.

In: Diabetes, Obesity and Metabolism, Vol. 21, No. 4, 01.04.2019, p. 772-780.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM)

T2 - Diabetes, Obesity and Metabolism

AU - Wittert, Gary

AU - Atlantis, Evan

AU - Allan, Carolyn

AU - Bracken, Karen

AU - Conway, Ann

AU - Daniel, Mark

AU - Gebski, Val

AU - Grossmann, Mathis

AU - Hague, Wendy

AU - Handelsman, David J.

AU - Inder, Warrick

AU - Jenkins, Alicia

AU - Keech, Anthony

AU - McLachlan, Robert

AU - Robledo, Kristy

AU - Stuckey, Bronwyn

AU - Yeap, Bu B.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Low circulating testosterone is associated with an increased risk of developing type 2 diabetes (T2DM) in overweight men with impaired glucose tolerance (IGT). Aims: To determine in a multi-centre, double-blinded placebo-controlled randomized trial whether testosterone treatment combined with lifestyle intervention (Weight Watchers) relative to lifestyle intervention alone reduces T2DM incidence and improves glucose tolerance at 2 years. Study population: Overweight or obese men aged 50-74 years with a serum testosterone of ≤14 nmol/L and IGT or newly diagnosed T2DM established by an oral glucose tolerance test (OGTT). Setting, drug and protocol: Six Australian capital city-based tertiary care centres. Participants were randomized 1:1 and injected with testosterone undecanoate (1000 mg/4 mL) or vehicle (4 mL castor oil), at baseline, 6 weeks and 3-monthly thereafter. Primary endpoints: (a) Proportion of participants with 2-hour OGTT ≥11.1 mmol/L at 2 years, and (b) a difference at 2 years ≥0.6 mmol/L in the mean 2-hour OGTT glucose between treatments. Secondary endpoints: Fasting insulin, HbA1c, body composition, maximal handgrip strength; sexual function and lower urinary tract symptoms; serum sex steroids and sex hormone binding globulin; mood and psychosocial function; adherence to lifestyle intervention; and healthcare utilization and costs. Safety: Overseen by an Independent Data Safety Monitoring Committee. Haematocrit, lipids and prostate-specific antigen (PSA) are assessed 6-monthly and information relating to haematological, urological and cardiovascular adverse events from each clinic visit. Sub-studies: (a) Changes in bone density and micro-architecture, (b) motivation and behaviour, (c) telomere length, (d) extended treatment up to 4 years, and (e) hypothalamo-pituitary testicular axis recovery at treatment end.

AB - Background: Low circulating testosterone is associated with an increased risk of developing type 2 diabetes (T2DM) in overweight men with impaired glucose tolerance (IGT). Aims: To determine in a multi-centre, double-blinded placebo-controlled randomized trial whether testosterone treatment combined with lifestyle intervention (Weight Watchers) relative to lifestyle intervention alone reduces T2DM incidence and improves glucose tolerance at 2 years. Study population: Overweight or obese men aged 50-74 years with a serum testosterone of ≤14 nmol/L and IGT or newly diagnosed T2DM established by an oral glucose tolerance test (OGTT). Setting, drug and protocol: Six Australian capital city-based tertiary care centres. Participants were randomized 1:1 and injected with testosterone undecanoate (1000 mg/4 mL) or vehicle (4 mL castor oil), at baseline, 6 weeks and 3-monthly thereafter. Primary endpoints: (a) Proportion of participants with 2-hour OGTT ≥11.1 mmol/L at 2 years, and (b) a difference at 2 years ≥0.6 mmol/L in the mean 2-hour OGTT glucose between treatments. Secondary endpoints: Fasting insulin, HbA1c, body composition, maximal handgrip strength; sexual function and lower urinary tract symptoms; serum sex steroids and sex hormone binding globulin; mood and psychosocial function; adherence to lifestyle intervention; and healthcare utilization and costs. Safety: Overseen by an Independent Data Safety Monitoring Committee. Haematocrit, lipids and prostate-specific antigen (PSA) are assessed 6-monthly and information relating to haematological, urological and cardiovascular adverse events from each clinic visit. Sub-studies: (a) Changes in bone density and micro-architecture, (b) motivation and behaviour, (c) telomere length, (d) extended treatment up to 4 years, and (e) hypothalamo-pituitary testicular axis recovery at treatment end.

KW - body composition

KW - cardiovascular

KW - motivation

KW - obesity

KW - prevention

KW - testosterone

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85059541071&partnerID=8YFLogxK

U2 - 10.1111/dom.13601

DO - 10.1111/dom.13601

M3 - Article

VL - 21

SP - 772

EP - 780

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 4

ER -